A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder

Journal of Clinical Psychiatry

Volumn 63, Issue 12, 2002, Pages 1148-1155

  Zajecka, John M ^a   Weisler, Richard ^a   Sachs, Gary ^a   Swann, Alan C ^a   Wozniak, Patricia ^a   Sommerville, Kenneth W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; CHLORAL HYDRATE; LORAZEPAM; OLANZAPINE; VALPROATE SEMISODIUM; ZOLPIDEM;

ADULT; ANTICHOLINERGIC EFFECT; ARTICLE; BIPOLAR DISORDER; CATATONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSIVE PSYCHOSIS; DIABETIC KETOACIDOSIS; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; GLUCOSE INTOLERANCE; HAMILTON SCALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SLEEP DISORDER; SOMNOLENCE; SPEECH DISORDER; WEIGHT GAIN; XEROSTOMIA;

EID: 0036936014     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n1210     Document Type: Article

References (33)

1. Keller MB, Baker LA. Bipolar disorder: epidemiology, course, diagnosis, and treatment. Bull Menninger Clin 1991;55:172-181
2. Bebbington P, Ramana R. The epidemiology of bipolar affective disorder. Soc Psychiatry Psychiatr Epidemiol 1995;30:279-292
3. Pope HG Jr, McElroy SL, Keck PE Jr, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991;48:62-68
4. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271:918-924
5. Papatheodorou G, Kutcher SP, Katic M, et al. The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults: an open clinical trial. J Clin Psychopharmacol 1995;15:110-116
6. Keck PE Jr, McElroy SL. The new antipsychotics and their therapeutic potential. Psychiatr Ann 1997;27:320-331
7. Frye MA, Ketter TA, Altshuler LL, et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 1998;48:91-104
8. Berk M, Ichim L, Brooks S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999; 14:339-343
9. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999;156:702-709
10. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania. Arch Gen Psychiatry 2000;57:841-849
11. Tohen M, Baker RW, Altshuler L, et al. Olanzapine versus divalproex for the treatment of acute mania [poster]. Presented at the 13th annual congress of the European College of Neuropsychopharmacology; Sept 9-13, 2000; Munich, Germany
12. Hirschfeld RMA, Allen MH, McEvoy J, et al. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry 1999;60:815-818
13. Bowden CL. Dosing strategies and time course of response to antimanic drugs. J Clin Psychiatry 1996;57(suppl 13):4-9
14. Keck PE Jr, Nabulsi AA, Taylor JL, et al. A pharmacoeconomic model of divalproex vs lithium in the acute and prophylactic treatment of bipolar I disorder. J Clin Psychiatry 1996;57:213-222
15. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV. New York, NY: Biometric Research, New York State Psychiatric Institute; 1995
16. Spitzer RL, Endicott J. Schedule for Affective Disorders and Schizophrenia-Change Version, Third Edition, New York, NY: Biometric Research, New York State Psychiatric Institute; 1978
17. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
19. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
20. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;45(suppl 212):11-19
21. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
22. Melkersson KI, Hulting A-L, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000;61:742-749
23. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767-770
24. Iqbal N, Oldan RL, Baird G, et al. Diabetes mellitus induced by atypical antipsychotics. Presented at the 52nd annual meeting of the American Psychiatric Association Institute on Psychiatric Services; Oct 25-29, 2000; Philadelphia, Pa
25. Gidal B, Spencer N, Maly M, et al. Valproate-mediated disturbances of hemostasis. Neurology 1994;44:1418-1422
26. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-783
27. Bettinger TL, Mendelson SC, Dorson PC, et al. Olanzapine-induced glucose regulation. Ann Pharmacother 2000;34:865-867
28. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999;40:438-443
29. Rigalleau V, Gatta B, Bonnaud S, et al. Diabetes as a result of atypical antipsychotic drugs: a report of three cases. Diabet Med 2000;17:484-486
30. Von Hayek D, Huttl V, Reiss J, et al. Hyperglycemia and ketoacidosis associated with olanzapine. Nervenarzt 1999;70:836-837
31. Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus [letter]. Am J Psychiatry 1999;156:1471
32. Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment [letter]. Diabetes Care 1999;22:1002-1003
33. Ober SK, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine [letter]. Am J Psychiatry 1999;156:970